Bringing treatments designed to restore the balance of the immune system to patients who hope to restore the balance in their lives.
Equillium is actively recruiting individuals to participate in a clinical trial for acute graft-versus-host disease (aGVHD).
Itolizumab is a clinical-stage, first-in-class immune-modifying monoclonal antibody that targets the CD6-ALCAM signaling pathway to selectively downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response.
Arising from a proprietary discovery platform, the peptides utilize a novel modality to selectively inhibit multiple disease driving cytokines, while leaving other immune regulatory pathways intact.